Home
Roivant

Roivant Market Share Analysis for August 2026

Roivant Sciences Ltd. is a healthcare company focused on applying technology to drug development and building subsidiary biotech and healthcare technology companies. It was founded in 2014 by Vivek Ramaswamy.

Health > Biotechnology and Pharmaceuticals

Domainroivant.com

Year Founded2014

Employees501 - 1000

Annual Revenue$25M - $50M

Roivant

Roivant (including company regionals)

roivant.com

See more website traffic and engagement information

Roivant Revenue up to August 2026 is 25M - 50M

revenue generated by Roivant top domains

Roivant top domains revenue over 3 years

Revenue for Roivant top domains

roivant.com25M - 50M

See more with Sales Intelligence

Total visits to Roivant's top domains

Understand Roivant market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

roivant.com37.8K

See more with Sales Intelligence

Avg. visit duration in Roivant's top domains

Analyze Roivant engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

roivant.com00:02:17

See more with Sales Intelligence

Avg. pageviews on Roivant's top domains

See how Roivant keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

roivant.com2.71

See more with Sales Intelligence

Roivant top competitors by domain

Top similar sites in August 2026, ranked by their affinity

immunovant.comCompany NameImmunovantEmployees201 - 500HQUnited States, New York, New York CityAnnual revenue$5M - $10MTotal visits5.5KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Roivant

These are the website technologies, by industry, used by Roivant top domains

Conversion & Analytics (5)

Google Analytics

Content Management System (4)

WordPress

Email Services (4)

G Suite

Mobile (3)

Meta Viewport

More Technologies

10

See all

News & Signals from Roivant

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsRoivant attended event European Respiratory Society (ERS) International Congress 2026 on Jul 1st '26.BASEL, Switzerland and LONDON and NEW YORK, Sept. 06, 2026 (GLOBE NEWSWIRE) - Roivant (Nasdaq: ROIV) and Pulmovant today announced that results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented at the European Respiratory Society (ERS) International Congress 2026 at 12:15 CEST (6:15 a.m. ET) on Tuesday, September 8, 2026, by Marc Humbert, MD, PhD, Professor of Respiratory Medicine at Université Paris-Saclay and Director of the French National Reference Center for Pulmonary Hypertension.

NewsRoivant launched LISRAYA on Aug 28th '26.* The FDA approved and Roivant launched LISRAYA (brepocitinib), described as the first targeted and oral treatment for adult dermatomyositis.